AR124937A1 - Mutación estabilizante de trímeros de proteínas de la envoltura del vih - Google Patents
Mutación estabilizante de trímeros de proteínas de la envoltura del vihInfo
- Publication number
- AR124937A1 AR124937A1 ARP220100371A ARP220100371A AR124937A1 AR 124937 A1 AR124937 A1 AR 124937A1 AR P220100371 A ARP220100371 A AR P220100371A AR P220100371 A ARP220100371 A AR P220100371A AR 124937 A1 AR124937 A1 AR 124937A1
- Authority
- AR
- Argentina
- Prior art keywords
- hiv
- numbering
- recombinant
- protein
- env protein
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 230000035772 mutation Effects 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 12
- 102100034353 Integrase Human genes 0.000 abstract 8
- 108010078428 env Gene Products Proteins 0.000 abstract 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 abstract 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 239000013638 trimer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Reivindicación 1: Una proteína de la envoltura (Env) del virus de la inmunodeficiencia humana (VIH) recombinante que comprende uno de los aminoácidos triptofano (Trp), fenilalanina (Phe), metionina (Met) o leucina (Leu) en la posición 650, en donde la numeración de las posiciones es de acuerdo con la numeración en la gp160 de la forma aislada HXB2 del VIH-1. Reivindicación 11: Un complejo trimérico que comprende un oligómero no covalente de tres proteínas Env del VIH recombinantes idénticas de cualquiera de las reivindicaciones 1 - 10. Reivindicación 12: Una partícula, preferiblemente un liposoma o una nanopartícula, que expresa sobre su superficie una proteína Env del VIH recombinante de cualquiera de las reivindicaciones 1 a 10 o un complejo trimérico de la reivindicación 11. Reivindicación 13: Una molécula de ácido nucleico aislada que codifica una proteína Env del VIH recombinante de cualquiera de las reivindicaciones 1 a 10. Reivindicación 14: Un vector que comprende la molécula de ácido nucleico aislada de la reivindicación 13 ligada operativamente a un promotor. Reivindicación 16: Una célula huésped que comprende la molécula de ácido nucleico aislada de la reivindicación 13 o el vector de la reivindicación 14 ó 15. Reivindicación 17: Un método para producir una proteína Env del VIH recombinante, que comprende cultivar la célula huésped de la reivindicación 16 en condiciones adecuadas para la producción de la proteína Env del VIH recombinante. Reivindicación 18: Una composición que comprende la proteína Env del VIH recombinante de cualquiera de las reivindicaciones 1 a 10, el complejo trimérico de la reivindicación 11, la partícula de la reivindicación 12, la molécula de ácido nucleico aislada de la reivindicación 13 o el vector de la reivindicación 14 ó 15 y un vehículo farmacéuticamente aceptable. Reivindicación 19: Un método para mejorar la formación de trímeros de una proteína Env del VIH, comprendiendo el método sustituir un residuo de aminoácido en la posición 650 de una proteína Env del VIH parental por uno de Trp, Phe, Met o Leu, preferiblemente por Trp o Phe, en donde la numeración de las posiciones es de acuerdo con la numeración en la gp160 de la forma aislada HXB2 del VIH-1. Reivindicación 20: Una proteína de la envoltura (Env) del virus de la inmunodeficiencia humana (VIH) recombinante que comprende histidina (His) en la posición 108, en donde la numeración de la posición es de acuerdo con la numeración en la gp160 de la forma aislada HXB2 del VIH-1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21158800 | 2021-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124937A1 true AR124937A1 (es) | 2023-05-24 |
Family
ID=74732664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100371A AR124937A1 (es) | 2021-02-23 | 2022-02-22 | Mutación estabilizante de trímeros de proteínas de la envoltura del vih |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220265813A1 (es) |
| EP (1) | EP4297778A1 (es) |
| JP (1) | JP2024509769A (es) |
| KR (1) | KR20230150269A (es) |
| CN (1) | CN116867517A (es) |
| AR (1) | AR124937A1 (es) |
| AU (1) | AU2022224967A1 (es) |
| CA (1) | CA3211197A1 (es) |
| MX (1) | MX2023009835A (es) |
| TW (1) | TW202302622A (es) |
| WO (1) | WO2022180007A1 (es) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| WO2004103312A2 (en) * | 2003-05-19 | 2004-12-02 | Progenics Pharmaceuticals, Inc. | Peptides useful as hiv fusion inhibitors |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| DK2358757T3 (da) | 2008-11-18 | 2019-01-02 | Beth Israel Deaconess Medical Ct Inc | Antivirale vacciner med forbedret cellulær immunogenicitet |
| WO2011005799A2 (en) | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| CN102711794B (zh) | 2010-01-04 | 2015-11-25 | Kj生物科学有限公司 | 用于疫苗和诊断学的Dps融合蛋白 |
| GB201108879D0 (en) | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| CA3200425A1 (en) | 2012-11-16 | 2014-05-22 | Peter ABBINK | Recombinant adenoviruses and use thereof |
| WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| US10400015B2 (en) * | 2014-09-04 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| JP6510149B2 (ja) | 2015-12-15 | 2019-05-08 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
| IL294832A (en) | 2016-09-15 | 2022-09-01 | Janssen Vaccines Prevention B V | HIV envelope proteins with trimer-stabilizing mutations |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| CA3069052A1 (en) | 2017-07-19 | 2019-01-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
| CN111163799A (zh) | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
| US11136356B2 (en) * | 2017-10-16 | 2021-10-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant HIV-1 envelope proteins and their use |
| CN111295391B (zh) | 2017-10-31 | 2023-12-05 | 扬森疫苗与预防公司 | 腺病毒及其用途 |
| MA50502A (fr) | 2017-10-31 | 2020-09-09 | Janssen Vaccines & Prevention Bv | Adénovirus et utilisations associées |
-
2022
- 2022-02-22 EP EP22707124.8A patent/EP4297778A1/en active Pending
- 2022-02-22 JP JP2023550223A patent/JP2024509769A/ja active Pending
- 2022-02-22 US US17/651,973 patent/US20220265813A1/en active Pending
- 2022-02-22 TW TW111106284A patent/TW202302622A/zh unknown
- 2022-02-22 AU AU2022224967A patent/AU2022224967A1/en active Pending
- 2022-02-22 KR KR1020237026810A patent/KR20230150269A/ko unknown
- 2022-02-22 AR ARP220100371A patent/AR124937A1/es unknown
- 2022-02-22 CA CA3211197A patent/CA3211197A1/en active Pending
- 2022-02-22 CN CN202280015572.XA patent/CN116867517A/zh active Pending
- 2022-02-22 MX MX2023009835A patent/MX2023009835A/es unknown
- 2022-02-22 WO PCT/EP2022/054336 patent/WO2022180007A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230150269A (ko) | 2023-10-30 |
| US20220265813A1 (en) | 2022-08-25 |
| TW202302622A (zh) | 2023-01-16 |
| CN116867517A (zh) | 2023-10-10 |
| AU2022224967A9 (en) | 2024-05-16 |
| EP4297778A1 (en) | 2024-01-03 |
| MX2023009835A (es) | 2023-09-04 |
| JP2024509769A (ja) | 2024-03-05 |
| AU2022224967A1 (en) | 2023-07-27 |
| WO2022180007A1 (en) | 2022-09-01 |
| CA3211197A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126987A2 (es) | Inmunoconjugados | |
| HRP20201458T1 (hr) | Trimer koji stabilizira mutacije proteina omotača hiv | |
| Skehel et al. | Studies on the primary structure of the influenza virus hemagglutinin. | |
| AU2007327829B2 (en) | Coiled-coil lipopeptide helical bundles and synthetic virus-like particles | |
| HRP20211715T1 (hr) | Trans-replicirajuća rnk | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| WO2017205786A1 (en) | Cell permeable peptidomimetic macrocycles | |
| JP4682251B2 (ja) | 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド | |
| AR056138A1 (es) | Procedimiento para la expresion recombinante de un polipeptido | |
| Garnier et al. | Recent advances and remaining problems in HIV assembly | |
| Suzuki et al. | The chemical structure of polymyxin E: the identities of polymyxin E1 with colistin A and of polymyxin E2 with colistin B | |
| KR20050098863A (ko) | 이량체화 펩티드 | |
| RU2014135703A (ru) | Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2, h2n2 и b | |
| AR124937A1 (es) | Mutación estabilizante de trímeros de proteínas de la envoltura del vih | |
| US11666630B2 (en) | Polypeptides for managing viral infections | |
| KR102608122B1 (ko) | 도데카펩타이드의 개선된 제조 방법 | |
| MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
| CL2022002208A1 (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación | |
| AR088028A1 (es) | Proteinas h5, de h5n1 para un uso medicinal | |
| AR041765A1 (es) | Vacuna a dna para la profilaxis y el tratamiento de infeccion por hiv | |
| AR041764A1 (es) | Vacuna basada en polinucleotidos y proteinas derivados del vih | |
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| JPWO2021070696A5 (es) | ||
| JP2019506840A (ja) | 抗ウイルス剤としてのペプチドおよびこのための使用 | |
| CO2023000048A2 (es) | Conjugados de citoquina |